What kind of treatment are available in deep vein thrombosis prevention?;Quels sont les moyens thérapeutiques (physiques, mécaniques, médicamenteux) disponibles et leurs modalités de surveillance:?

Annales Francaises d'Anesthesie et de Reanimation

Volumn 24, Issue 8, 2005, Pages 862-870

  Leclerc Foucras, S ^a   Mertes, P M ^b   N'Guyen, P ^c  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

^c SERVICE DE DERMATOLOGIE   (France)

Author keywords

Low Molecular Weight Heparin; Mechanical prophylaxis; New antithrombotic drugs; Prevention of deep vein thrombosis

Indexed keywords

DEEP VEIN THROMBOSIS; EVIDENCE BASED MEDICINE; HUMAN; MEDICAL PRACTICE; MEDLINE; OBSTETRIC OPERATION; OBSTETRICS; PRACTICE GUIDELINE; PROPHYLAXIS; REVIEW;

EID: 23744511589     PISSN: 07507658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annfar.2005.06.005     Document Type: Article

References (70)

1. J. Emmerich Fŕquence et facteurs de risque de la maladie veineuse thromboembolique Rev. Prat. 53 2003 14 19
2. J. Bouthier The venous thrombotic risk in nonsurgical patients Drugs 52 Suppl.7 1996 16 29
3. M.D. Silverstein, J.A. Heit, D.N. Mohr, T.M. Petterson, W.M. O'Fallon, and L.J. Melton III Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25:year population-based study Arch. Interm. Med. 158 1998 585 593
4. Geerts WH, Heit JA, Clagget GP, Pineo GF, Colwell CW, et al. Prevention of venous thromboembolism. Chest;2001:; 119(Suppl):132S-175S.
5. M.M. Samama Applying risk assessment models in general surgery: effective risk stratification Blood Coag. Fibrinolysis 10 Suppl 1999 79 84
6. G. Guyatt, H. Schunmann, D. Cook, R. Jaeschke, S. Pauker, and H. Bucher Grades of recommendation for antithrombotic agents Chest 119 Suppl 2001 3S 7S
7. M. Belen Moscoso, D. Mottier, M. Nonent, F. Couturaud, K. Lacut, S. Louis, and C. Leroyer Le diagnostic de la maladie veineuse thromboembolique en post-oṕratoire Press Med 32 2003 852 859
8. J.A. Heit, M.D. Silverstein, D.N. Mohr, T.M. Petterson, W.M. O'Fallon, and L.J. Melton III Predictors of survival after deep vein thrombosis and pulmonary embolism; a population-based cohort study Arch Intern Med 159 1999 445 453
9. L. Drouet Pathologie thromboembolique veineuse. Nouveaux facteurs de risque acquis ou nouvelles sur les facteurs de risqú acquis Arch Mal Cur 94 2001 1318 1326
10. C.M. Samama Groupe d'int́r̂t en h́mostase ṕrioṕratoire (GIHP) Les diff́rents niveaux de risque thromboembolique en chirurgie C.M. Samama P. de Moerloose J.F. Hardy P. Sí A. Steib H́morragies et thromboses ṕrioṕratoires: approche pratique 2000 Masson Paris 177 185
11. S. Sevitt, and N. Gallagher Venous thrombosis and pulmonary embolism Br. J. Surg. 48 1961 475 489
12. G. Agnelli, F. Piovella, P. Buoncristiani, P. Severi, M. Pini, and A. D'Angelo Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery N. Engl. J. Med. 339 1998 80 85
13. O. Agu, G. Hamilton, and D. Baker Graduated compression stockings in the prevention of venous thromboembolism Br. J. Surg. 86 1999 992 1004
14. P.S. Wells, A.W. Lensing, and J. Hirsh Graduated compression stockings in the prevention of postoperative venous thromboembolism: a meta-analysis Arch. Intern. Med. 154 1994 67 72
15. Y. Chapuis, B. Augureau, F. Clergue Comit́ scientifique thrombose de l'AP-HP Prophylaxie des thromboses veineuses postoṕratoires: recommandations de l'assistance publique-hôpitaux de Paris Sang Thromb. Vaiss. 7 1995 119 129
16. J. Ninet, M.H. Horellou, J.J. Darjinoff, C. Caulin, and A. Leizorovicz Conf́rence de consensus, 8 mars 1991, Paris. Prophylaxie des thromboses veineuses profondes et des embolies pulmonaires postoṕratoires (chirurgie visćrale, gyńcologique et orthoṕdique) Ann. Fr. Anesth. Reanim. 10 1991 417 421
17. S.J. Lewis, M. Egger, P.A. Sylvester, and S.T. Topic Early enteral feeding "nil per mouth" after gastrointestinal surgery: systematic review and meta-analysis of controlled trials BMJ 323 2001 1 5
18. H. Kehlet Multimodal approach to control postoperative pathophysiology and rehabilitation Br. J. Anaesth. 78 1997 606 617
19. e Congr̀s national d'anesth́sie et de ŕanimation 2004 (Paris)
20. J.A. Hoocker, P.F. Lachiewicz, and S.S. Kelley Efficacy of prophylaxis against thromboembolism with intermittent pneumatic compression after primary and revision total hip arthroplasty J. Bone Joint Surg. Am. 81 1999 690 696
21. L.A. Killewich, M.A. Cahan, D.J. Hanna, M. Murakami, T. Uchida, and L.A. Wiley The effect of external pneumatic compression on regional fibrinolysis in a prospective randomized trial J. Vasc. Surg. 36 2002 953 958
22. Y. Okuda, T. Kitajima, H. Egawa, S. Hamaguchi, S. Yamaguchi, and H. Yamazaki A combination of heparin and an intermittent pneumatic compression device may be more effective to prevent deep-vein thrombosis in the lower extremities after laparoscopic cholecystectomy Surg. Endosc. 16 2002 781 784
23. M.J.F. Fordyce, and R.S.M. Ling A venous foot pump reduces thrombosis after total hip replacement Bone Joint Surg. 74 B 1992 45 49
24. G.J. Stranks, N.A. McKenzie, and M.L. Grover The A-V Impulse System reduces deep-vein thrombosis and swelling after hemi-arthroplasty for hip fracture J. Bone Joint Surg. 74 B 1992 775 778
25. D. Warwick, J. Harrison, S. Whitehouse, A. Mitchelmore, and M. Thornton A randomised comparison of a foot pump and low-molecular-weight heparin in the prevention of deep-vein thrombosis after total knee replacement J. Bone Joint Surg. Br. 84 B 2002 344 350
26. R.P. Pitto, H. Hamer, W. Heiss-Dunlop, and J. Kuehle Mechanical prophylaxis of deep-vein thrombosis after total hip replacement a randomised clinical trial J. Bone Joint Surg. Br. 86 2004 639 649
27. R.J. Morris, and J.P. Woodcock Evidence-based compression: prevention of stasis and deep vein thrombosis Ann. Surg. 239 2004 162 171
28. S.T. Woolson Intermittent pneumatic compression prophylaxis for proximal deep venous thrombosis after total hip replacement J. Bone Joint Surg. Am. 11 1996 1735 1740
29. T.M. Hyers Management of venous thromboembolism. Past, present, and future Arch. Intern. Med. 163 2003 759 768
30. J. Barŕ, N. Rosencher Groupe d'int́r̂t en h́mostase ṕrioṕratoire (GIHP) Pŕvention ḿdicamenteuse de la maladie thromboembolique veineuse C.M. Samama P. de Moerloose J.F. Hardy P. Sí A. Steib H́morragies et thromboses ṕrioṕratoires: approche pratique 2000 Masson Paris 193 204
31. J.A. Grinsberg, M.A. Crowther, R.H. White, and T.L. Ortel Anticoagulation therapy Hematology (Am. Soc. Hematol Educ Program) 2001 339 357
32. B. Boneu, P. Potron, Y. Gruel, P. Nguyen, and M. Aiach Utilisation des h́parines en pratique ḿdicale courante Sang Thromb. Vaiss. 12 2000 12 25
33. K.B. Freedman, K.R. Brookenthal, R.H. Fitzgerald Jr., S. Williams, and J.H. Lonner A meta-analysis of thromboembolic prophylaxis following elective hip replacement J. Bone Joint Surg. Am. 82A 2000 929 938
34. H.R. Buller, G. Agnelli, R.D. Hull, T.M. Hyers, M.H. Prins, and G.E. Raskob Antithrombotic therapy for venous thromboembolic disease: the seventh ACCP conference on antithrombotic and thrombolytic therapy Chest 126 Suppl 2004 401S 428S
35. I. Gouin-Thibault, E. Pautas, and V. Siguret Safety profile of different low-molecular weight heparins used at therapeutic dose Drug Saf. 28 2005 333 349
36. V. Siguret, E. Pautas, and I. Gouin Low molecular weight heparin treatment in elderly subjects with or without renal insufficiency: new insights between June 2002 and March 2004 Curr. Opin. Pulm. Med. 10 2004 366 370
37. N. Thorevska, Y. Amoateng-Adjepong, R. Sabahi, I. Schiopescu, A. Salloum, and V. Muralidharan Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs enoxaparin Chest 125 2004 856 863
38. M. Levine, M. Gent, J. Hirsh, J. Leclerc, D. Anderson, and J. Weitz A comparison of low-molecular-weight heparin administered primarily at home with unfractionned in the hospital for proximal deep-vein thrombosis N. Engl. J. Med. 334 1996 677 681
39. G.H. Westrich, S.B. Haas, P. Mosca, and M. Peterson Meta-analysis of thromboembolic prophylaxis after total knee arthroplasty J. Bone Joint Surg. Br. 82 2000 795 798
40. W.H. Geerts, G.F. Pineo, J.A. Heit, D. Bergqvist, M.R. Lassen, and C.W. Colwell Prevention of venous thromboembolism: the seventh ACCP conference on antithrombotic and thrombolytic therapy Chest 126 2004 338 400
41. A. Planes, M.M. Samama, A.W. Lensing, H.R. Buller, J. Barre, and N. Vochelle Prevention of deep vein thrombosis after hip replacement: comparison between two low molecular weight heparins, tinzaparin and enoxaparin Thromb. Haemost. 81 1999 22 25
42. L. Drouet, Y. Gruel, and P. Mismetti Les nouveaux antithrombotiques Sang Thromb. Vaiss. 12 2000 48 55
43. T. Ibbotson, and C.M. Perry Danaparoid. A review of its use in thromboembolic and coagulation disorders Drugs 62 2002 2283 2314
44. B. Tardy-Poncet, J. Reynaud, B. Tardy, P. Mahul, P. Mismetti, and A.M. Beraud Thromboṕnie induite par l'h́parine: traitement par l'ORG 10172 Presse Med. 25 1996 751 755
45. V. DiCarlo, G. Agnelli, P. Prandoni, S. Coccheri, G.F. Gensini, and F. Gianese Dermatan sulphate for the prevention of postoperative venous thromboembolism in patients with cancer: DOS (dermatan sulphate in oncologic surgery) Study group Thromb. Haemost. 82 1999 30 34
46. e congr̀s national d'anesth́sie et de ŕanimation. Conf́rences d'actualisation 2000 Elservier Paris 439 445
47. J.M. Walenga, W.P. Jeske, L. Bara, M.M. Samama, and J. Fareed Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide Thromb. Res. 86 1997 1 36
48. A.G.G. Turpie, A.S. Gallus, and J.A. Hoek A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement N. Engl. J. Med. 344 2001 619 625
49. G. Agnelli, and F. Sonaglia Perspectives on antithrombotic agents: from unfractionated heparin to new antithrombotics Haematologica 87 2002 757 770
50. J.I. Weitz, and J. Hirsh New anticoagulant drugs Chest 119 suppl 2001 95S 107S
51. A. Greinacher, H. Volpel, and U. Janssens Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia Circulation 99 1999 73 80
52. T.L. Ortel, and B.H. Chong New treatment options for heparin-induced thrombocytopenia Semin. Hematol. 35 1998 26 34
53. ®) with unfractionated heparin in patients having a total hip replacement J. Bone Joint Surg. Am. 79 1997 326 333
54. I. Elalamy, J.P. Tillement, and M.M. Samama Caract́ristiques pharmacologiques des antivitamines K Sem. Hop. Paris 13-14 1995 401 408
55. J.F. Schved, P. de Moerloose, B. Jude, and P. Toulon Utilisation des antivitamines K en pratique ḿdicale courante Sang Thromb. Vaiss. 12 2000 26 39
56. P.T. Sawicki A structurd teaching and self management program for patient receiving oral anticoagulation. A randomized controlled trial. Working group for the study of patient self-management of oral anticoagulation JAMA 281 1999 145 150
57. C.M. Oakley Anticoagulation and pregnancy Eur. Heart J. 16 1995 1317 1319
58. R. Mc Kenna, E.R. Cole, and U. Vasan Is warfarine sodium contraindicated in the lacting mother J. Pediatr. 103 1983 325 327
59. Agence franȩaise pour la sécurit́ des produits de santé, AFSSAPS. Le bon usage des traitements anticoagulants par antivitamines K (AVK). [08/01/04]. Available from URL: http://afssaps.sante.fr/.
60. D. Gustaffson, J.E. Nystrom, and S. Carlsson Pharmacodynamic properties of ximelagatran, a prodrug of the direct thrombin inhibitor melagatran intended for oral use Blood 94 1999 26a [abstract]
61. B.I. Eriksson, G. Agnelli, A.T. Cohen, O.E. Dahl, M.R. Lassen, P. Mouret on behalf of the EXPRESS study group The direct thrombin inhibitor melagatran followed by oral melagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the Express study J. Thromb. Haemost. 1 2003 2490 2496
62. B.I. Eriksson, A.C. Arfwidsson, L. Frison, U.G. Eriksson, A. Bylock, and P. Kalebo A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: Methro I. MElagatran for THRombin inhibition in Orthopaedic surgery Thromb. Haemost. 87 2002 231 237
63. B.I. Eriksson, D. Bergqvist, P. Kulebo, S. Lindbratt, A. Bylock, and L. Frison Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the Methro II randomised trial Lancet 360 2002 1441 1447
64. B.I. Eriksson, G. Agnelli, A.T. Cohen, O.E. Dahl, P. Mouret, N. Rosencher METHRO III study group. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement Thromb. Haemost. 89 2003 288 296
65. S. Schulman, K. Wuhlander, T. Lundstrom, and S. Biling Clason Eriksson H for the THRIVE III Investigators. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran N. Engl. J. Med. 349 2003 1713 1721
66. Sportif III Investigators Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial Lancet 362 2003 1691 1698
67. L. Wallentin, R.G. Wilcox, W.D. Weaver, H. Emanuelsson, A. Goodvin, P. Nystrom for the ESTEEM Investigators. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial Lancet 362 2003 789 797
68. J.J. Badimon, M. Lettino, V. Toschi, V. Fuster, M. Berrozpe, and J.H. Chesebro Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques Circulation 99 1999 1780 1787
69. L. Drouet Nouveaux et futurs ḿdicaments antithrombotiques dans la maladie veineuse thromboembolique Rev. Prat. 53 2003 58 61
70. T. Lecompte New antithrombotic drugs (excluding plasminogen activators) Arch. Mal. Coeur Vaiss. 94 11 Suppl 2001 1225 1232